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Abstract—This work is aimed at the optimization of the phase composition, surface morphology, and micro-
structure of matrices based on octacalcium phosphate (OCP) in order to increase the maximum dose and
dosing accuracy of immobilized nucleic acids (NAs). It is determined that the modification of the scaffold
with magnesium leads to a 1.4-fold increase in binding of plasmid DNA, which can further be used for the
fabrication of medical products with the specified high concentration of biologically active NAs. Preliminary
in vitro evaluation shows that the addition of magnesium to OCP regulates metabolic activity of HEK-293FT
cell lines.
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INTRODUCTION
The annual number of patients who require recon-
structive operations because of bone injuries is partic-
ularly large. In principle, a sufficiently effective treat-
ment can be achieved using standard methods and
materials (ordinary bone substitute, such as Osteo-
matriks (Konektbiofarm, Russia), Kolapol-KP-3
(NPO Polistom, Russia), Cerasorb (Curasan, Ger-
many), Chronos (Synthes, Switzerland), and Trikafor
(BioNova, Russia)) [1]. However, the desired results,
namely, recovery of the initial quality of life, are not
achieved for a large number of patients. This is caused
by the fact that the number of cambial cells and bio-
logically active substances in the defect zone, which
induce reparative regeneration of tissues, is minimized
and does not provide a complete histotypic recovery at
large damage of tissues and organs; also, the presence
of comorbidity and risk factors complicates the clini-
cal setting [1]. Effective therapy in these cases can be
provided only using materials and methods which
affect the reparative regeneration of tissues, compen-
sate for lost structures, replenish the cambial reserve,
provide the factors that control the recovery process,
and so on [2].
One of the routes for the solution of this problem is
the employment of gene-activated bone substitute,
which represent a particular class of medical products
for bone grafting [3]. They are featured by the presence
of genetic constructs, more specifically, biologically
active nucleic acids (NAs), which carry the genes of
therapeutic protein factors combined with the syn-
thetic scaffold. To fabricate the latter, a rather large
spectrum of materials are used today. In our opinion,
the use of ceramic based on calcium phosphates
(CPs), which represents a synthetic counterpart of
bone tissue, is quite promising.
After implantation into the bone defect or the
region of bone atrophy, genetic constructs are released
from bone substitute, enter the cells of the recipient
bed (immune competent cells, fibroblasts, and osteo-
blasts), and are expressed there for a particular time
period to produce therapeutic protein, which is coded
by the gene constructs [3, 4].
However, gene-activated materials based on CPs
for tissue engineering possess some specific draw-
